PUBLIC HEALTH AND ECONOMIC IMPACT OF A HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR
Author(s)
ABSTRACT WITHDRAWN
OBJECTIVES: To assess the public health and economic impact of a human papillomavirus (HPV) vaccination program with a quadrivalent (HPV6/11/16/18) and bivalent (HPV 16/18) vaccine in 9-year-old females versus only-screening strategy in El Salvador. METHODS: A previously developed transmission dynamic mathematical model was adapted to evaluate the impact of routine vaccination of 9-year-old females in El Salvador. The model projected 80% coverage for two doses of both HPV vaccines. El Salvador specific data was used from literature where available; default values were used otherwise. Input data included demographic, behavioral, epidemiological and screening parameters, and direct treatment costs of HPV-related morbidities from a public health perspective. RESULTS: In a 100-year period, both HPV vaccines will reduce in the same level the HPV 16-18 related burden of disease and associated costs in females: CC (45.6%, 22,177), CIN 2/3 (69.4%; 81,440) and CIN1 (70.2%, 81,440). The cumulative percent reduction in deaths from cervical cancer after 100 years with both vaccines are projected to be 42.5% (9,709 deaths). As compared to a bivalent vaccination program, a quadrivalent vaccination program would result in additional reductions of HPV 6/11-related disease incidence/disease cases at the population level as follows in females: genital warts (78.3%; 488,977 cases) and HPV6/11-related CIN1 (78%; 25,904 cases) and also in males through herd immunity: genital warts in males (75.6%; 189,574 cases). Under the model assumptions, the disease management cost savings (cost of vaccination – disease costs avoided) were US$ 161, 688, 947 and US$ 40,561,361 for a quadrivalent (HPV6/11/16/18) and bivalent (HPV 16/18) vaccination program, respectively, over 100 years. Both HPV vaccines were cost savings with strongly dominating ICERs. CONCLUSIONS: In El Salvador, routine vaccination of 9-year-old females with a quadrivalent HPV6/11/16/18 vaccine has incremental public health and economic impact as compared to a bivalent HPV 16/18 vaccine.
Conference/Value in Health Info
2019-09, ISPOR Latin America 2019, Bogota, Colombia
Value in Health Regional, Volume 20S (October 2019)
Code
PIN10
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Public Health
Disease
Vaccines